OR WAIT null SECS
It was a very busy week for the Contemporary OB/GYN® team.
This week’s top articles included:
In addition to welcoming a newborn, parents may be unexpectedly billed for some hospitalization services, according to a research letter in JAMA Health Forum.
On June 2, 2021, ibrexafungerp (Brexafemme; Scynexis, Inc) was approved by the Food and Drug Administration for vulvovaginal candidiasis (VVC) in adult women and pediatric females who have begun menstruating. Ibrexafungerp is a triterpenoid antifungal that works by inhibiting the formation of the fungal cell wall. Ibrexafungerp (pronounced eye-BREX-ah-FUN-jerp) is the first approved drug of a novel class of antifungals.
Refer to this visual summary from SMFM wherever you practice.
Introducing Contemporary OB/GYN® Editorial Advisory Board member Yalda Afshar, MD, PhD.